Amitell Capital Pte Ltd Makes New $2.32 Million Investment in Elevance Health, Inc. $ELV

Amitell Capital Pte Ltd purchased a new position in Elevance Health, Inc. (NYSE:ELV) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,180 shares of the company’s stock, valued at approximately $2,320,000. Elevance Health comprises about 1.4% of Amitell Capital Pte Ltd’s holdings, making the stock its 27th largest holding.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Elevance Health by 0.6% in the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after acquiring an additional 141,747 shares during the last quarter. Sanders Capital LLC boosted its holdings in shares of Elevance Health by 24.7% in the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Elevance Health by 9.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock worth $1,429,498,000 after purchasing an additional 324,399 shares in the last quarter. Norges Bank bought a new position in shares of Elevance Health during the 2nd quarter valued at about $1,148,379,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Elevance Health by 4.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after buying an additional 112,020 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

Shares of ELV stock opened at $330.52 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market cap of $72.95 billion, a P/E ratio of 13.16, a P/E/G ratio of 1.81 and a beta of 0.50. The business’s 50 day moving average price is $351.06 and its 200-day moving average price is $335.28.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.23%.

Analyst Ratings Changes

Several brokerages have issued reports on ELV. Guggenheim cut their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a research report on Tuesday, February 3rd. Finally, Wells Fargo & Company lowered their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.